Talib Mays

Nguyen Xuan-Thanh-An, Talib Mays, van Schooneveld Mary J, Wijnholds Jan, van Genderen Maria M, Schalij-Delfos Nicoline E et al.

This 2-year study of CRB1 retinal dystrophies found visual acuity and fields stable, but microperimetry showed significant retinal sensitivity decline. Microperimetry may be a sensitive clinical trial endpoint for progression.

Talib Mays, Van Cauwenbergh Caroline, De Zaeytijd Julie, Van Wynsberghe David, De Baere Elfride, Boon Camiel J F et al.

CRB1 retinal dystrophies are progressive, causing early macular damage, with a potential gene therapy window before age 40 for RP and age 10 for LCA.

Talib Mays, van Schooneveld Mary J, Wijnholds Jan, van Genderen Maria M, Schalij-Delfos Nicoline E, Talsma Herman E et al.

This study of CRB1-RD patients found variable visual function and structural changes despite severe disease. This variability suggests imaging and functional tests are crucial for defining clinical trial endpoints, especially given the range of phenotypes.